Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erlotinib OSI/Roche/Genentech.

Tracy E Kim1, John R Murren

  • 1Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA. tracykim@snet.net

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2010
Same author

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2009
Same author

Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.

Cancer journal (Sudbury, Mass.)·2007
Same author

Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.

Clinical cancer research : an official journal of the American Association for Cancer Research·2007
Same author

Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.

The Lancet. Oncology·2006
Same author

Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.

Cancer biology & therapy·2005
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is being developed for solid tumors. Clinical trials are underway for non-small-cell lung cancer and pancreatic cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Erlotinib (CP-358774, OSI-774, Tarceva) is an orally active quinazoline derivative.
  • It functions as an epidermal growth factor receptor tyrosine kinase inhibitor.

Purpose of the Study:

  • To evaluate erlotinib as a potential treatment for solid tumors.
  • To assess its efficacy in monotherapy and combination therapy.

Main Methods:

  • Development of erlotinib is most advanced in non-small-cell lung cancer (NSCLC) and pancreatic cancer.
  • Phase III trials for NSCLC combination therapy began in July 2001.
  • Phase III trials for NSCLC monotherapy and pancreatic cancer combination therapy commenced in October 2001.
  • Phase I studies in Japan were initiated in January 2002.

Related Experiment Videos

Main Results:

  • Erlotinib is under joint development by Genentech, OSI, and Roche.
  • The compound is being investigated for various solid tumors including breast, head and neck cancers.

Conclusions:

  • Erlotinib shows promise for treating non-small-cell lung cancer and pancreatic cancer.
  • Ongoing clinical trials will further define its therapeutic role.